Over 137 million US adults qualify for semaglutide therapy for diabetes and weight management

A recent study found that over 137 million US adults are eligible for semaglutide therapy, surpassing the number eligible for statins. This increase is due to expanded uses for diabetes management, weight control, and cardiovascular disease prevention. The study analyzed data from the National Health and Nutrition Examination Survey, identifying eligibility based on diabetes status, body mass index, and cardiovascular history. Approximately 35 million adults qualify for diabetes treatment, while about 129 million meet weight management criteria. The findings highlight significant healthcare costs associated with semaglutide, as many eligible individuals may lack adequate insurance coverage. Understanding the demographics of these populations is essential for informing healthcare policies and managing costs effectively.